The use of antibodies against PD-1/PD-L1 in targeted therapy has demonstrated significant potential in various types of cancer, such as breast cancer [29, 30], colorectal cancer [31], lung cancer [32] and osteosarcoma [33]. The gene discussed is PDCD1; the disease is colorectal cancer.